Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pancreatic cancer
Stage/Subtype:  stage IV pancreatic cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 99 for your search:
Start Over
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: EP-GF-301, NCI-2013-02181, NCT01954992
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081FC00001, NCI-2015-00038, 2014-001589-85, NCT02184195
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 19211, NCI-2012-00026, NCT01506973
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, PS1313_A09PAMDREVW01, NCT01959139
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NLG2104, NCI-2014-02095, NCT02077881
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FGCL-3019-069, NCI-2015-01207, NCT02210559
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Gemcitabine Hydrochloride, Docetaxel, Capecitabine, Cisplatin, and Irinotecan Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: J14161, NCI-2015-00235, NCT02324543
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Tosedostat and Capecitabine in Treating Patients with Pancreatic Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201503074, NCI-2015-00425, NCT02352831
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PB1201, NCI-2013-01411, NCT01834235
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA212-115, NCI-2015-01260, 2015-000136-15, NCT02472977
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FF-10502-01, NCI-2016-00184, NCT02661542
Start Over